top of page

Next-Generation Ensitrelvir: A Computational Strategy for Improving SARS-CoV-2 Main Protease Inhibition

Writer: Yogy Simanjuntak
Yogy Simanjuntak
13 hours ago
4 min read
Computational Optimization of Ensitrelvir Reveals a Potential Next-Generation SARS-CoV-2 Main Protease Inhibitor
Computational Optimization of Ensitrelvir Reveals a Potential Next-Generation SARS-CoV-2 Main Protease Inhibitor

Clinical Relevance

Although COVID-19 has transitioned into an endemic disease, SARS-CoV-2 continues to pose a significant public health burden, particularly among older adults, immuno-compromised individuals, and patients with underlying comorbidities. The emergence of new viral variants and the potential development of antiviral resistance highlight the need for improved therapeutic interventions with greater clinical efficacy, a high barrier to resistance, and sustained activity against genetically diverse SARS-CoV-2 strains.

 

SARS-CoV-2 main protease (Mpro or nsp5), also known as 3C-like protease (3CLpro), is a highly conserved viral enzyme and one of the premier targets for antiviral drug development. 3CLpro plays a critical role in the viral replication and contributes to innate immune evasion. Furthermore, it has no close homologous counterpart in human cells, making it an attractive target for selective antiviral therapy. Several small-molecule inhibitors targeting 3CLpro have been developed and FDA-approved for the treatment of COVID-19 including ensitrelvir (EST).

 

In the phase 3 SCORPIO-HR trial, EST reduces viral RNA levels by approximately 0.72 log10 copies/mL compared with placebo on day 4. However, the time improvement to sustain symptom resolution is not statistically significant (12.5 Vs. 13.1 days). In the prophylactic setting, EST reduces the incidence of COVID-19 among household contacts from 9.0% to 2.9%, corresponding to a 67% relative risk reduction (RR 0.33; 95% CI 0.22–0.49). Notably, in the SCORPIO-SR clinical trial, several resistant SARS-CoV-2 strains are detected in EST-treated patients. Collectively, these findings raise concerns about the development of next-generation EST with enhanced antiviral potency and improved clinical effectiveness.

 

Computational Identification of Next-Generation EST

EST is an orally active, non-covalent, 3CLpro inhibitor with the molecular weight of 531.88 g/mol. EST consists of central core of triazinone ring system, indazole group attached via an imino linkage (blue rectangle), trifluorobenzene (orange circle), and triazole group (green rectangle) (Fig. A). To identify the next-generation of EST with potentially improved binding and physicochemical properties, I performed a computational structure-binding relationship analysis of three structural modifications while retaining the central core: 1) indazole group (EST-YS1), 2) indazole and trifluorobenzene (EST-YS5), 3) indazole, trifluorobenzene, and triazole (EST-YS9) (Fig. A).

 

Prior to computational docking analysis, I characterized the potential binding cavities of 3CLpro (PDB: 6lu7) using molecular cavity analysis. The analysis identified a prominent binding cavity with with a volume of 271. 08 Å3 and a surface area of 216. 19 Å2 (Fig. B). Notably, the catalytic dyad residues (HSD41 and CYS145) were located within this cavity (magenta, Fig. B).

 

EST formed hydrogen bonds with GLY143 or CYS145 (green lines, Fig. C) and exhibited additional contact interactions with key 3CLpro binding-pocket residues, including PHE140 and GLU166 (black lines, Fig. C). Interestingly, modification of the indazole group (EST-YS1; shown as cyan surface) brought the central core closer to CYS145 through hydrogen bonding, reducing the interaction distance from 2.55 Å in EST to 2.25 Å in EST-YS1, while maintaining a relatively similar contact distance with GLY143 (Fig. D and G). The combined indazole and trifluorobenzene modifications (EST-YS5; shown as cyan surface) shifted the binding orientation of the central core, promoting hydrogen-bond interactions with GLY143 and ionic interactions with HSD41 (Fig. E). The interaction with GLY143 may influence the local electrostatic environment of the oxyanion hole during enzymatic cleavage. In addition, EST-YS5 exhibited more extensive contact interactions with key 3CLpro binding-pocket residues, including HSD164, GLU166, and GLN192 (Fig. E). Finally, the combined modifications of the indazole, trifluorobenzene, and triazole groups (EST-YS9, shown as cyan surface) maintained interactions between the central core and HSD41 while increasing contact interactions with THR26 and several key 3CLpro binding-pocket residues, including ASN142, HSD164, GLU166, and GLN189 (Fig. F).

 

Regarding physicochemical properties, EST-YS9 exhibited an estimated logP of 1.16, slightly higher than that of EST (1.06), suggesting a modest increase in lipophilicity that could potentially favor passive membrane diffusion (Fig. G). Furthermore, EST-YS9 demonstrated a substantially more favorable calculated total binding energy, incorporating cavity attraction and binding free energy, compared with EST (-233.73 vs. -181.58 kcal/mol, respectively; Fig. G). EST-YS9 also exhibited a greater number of close hydrogen-bond and ionic interactions (≤3 Å) with key 3CLpro residues than EST (6 vs. 3–4 residues, respectively; Fig. G).

 

Take-Home Hypothesis & Clinical Implication

The moderate clinical efficacy of EST in certain treatment settings, together with the emergence of resistance-associated SARS-CoV-2 3CLpro mutations, underscores the clinical relevance of developing next-generation EST. Structural optimization through modifications of the indazole, trifluorobenzene, and triazole groups, as exemplified by EST-YS9, may improve molecular interactions with 3CLpro and potentially enhance its physicochemical properties, including lipophilicity, metabolic stability, and oral drug-like characteristics. Furthermore, EST-YS9 possesses a distinct chemical scaffold compared with currently approved 3CLpro inhibitors, making it an interesting candidate for further investigation. Nevertheless, experimental validation, including biochemical inhibition, antiviral activity, pharmacokinetic profiling, and resistance susceptibility assessments, will be essential to establish its therapeutic potential.

 

---------------------------------

HyVir would love to hear from you if this hypothesis proves to work.

Need sharper figures or references? Contact HyVir and get what you need!

Comments


Stay Connected with HyVir

  • Facebook
  • LinkedIn
bottom of page